"Oncology Biosimilars Market – Industry Trends and Forecast to 2029
Global Oncology Biosimilars Market, By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Blood Cancer, Others), Drug Class (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor, Others), Route of Administration (Intravenous, Subcutaneous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Data Bridge Market Research analyses that the oncology biosimilars market was valued at USD 4.00 billion in 2021 and is expected to reach USD 15.55 billion by 2029, registering a CAGR of 18.5% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Access Full 350 Pages PDF Report @
https://www.databridgemarketresearch.com/reports/global-oncology-biosimilars-market
A biosimilar is a generic counterpart of a well-known biologic medicine. Medications made from living substances such as cells, tissues, or proteins are known as biologic drugs. A biosimilar is a medication that is based on a biologic drug that has already been studied, produced, clinically tested for safety and effectiveness, and authorized by the US Food and Drug Administration (FDA). Since the biosimilar is based on the approved drug, the biologic medications are commonly referred to as reference drugs. The functions of biosimilar are same as the reference drugs and it is dependent to FDA approval.
**Segments**
- Global Oncology Biosimilars Market By Product Type
- Global Oncology Biosimilars Market By Distribution Channel
- Global Oncology Biosimilars Market By Application
- Global Oncology Biosimilars Market By End User
- Global Oncology Biosimilars Market By Geography
Biosimilars are complex biological products that are highly similar to already approved reference biologics. In the oncology sector, biosimilars have gained significant traction due to their potential to reduce the cost burden associated with cancer treatment while maintaining similar efficacy and safety profiles as their reference biologics. The market is segmented by product type, distribution channel, application, end-user, and geography. By product type, the market encompasses monoclonal antibodies, immunomodulators, and supportive care biosimilars. Within the distribution channel segment, hospitals, retail pharmacies, and online pharmacies play a crucial role in the supply chain of oncology biosimilars. Application-wise, oncology biosimilars find application in the treatment of various cancers such as breast cancer, lung cancer, colorectal cancer, and others. End users of these biosimilars include hospitals, clinics, and ambulatory surgical centers. Geographically, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
**Market Players**
- Amgen Inc.
- Biocon
- Celltrion Inc.
- Dr. Reddy's Laboratories Ltd.
- Fresenius Kabi AG
- Pfizer Inc.
- Samsung Bioepis
- Sandoz International GmbH
- STADA Arzneimittel AG
- Teva Pharmaceutical Industries Ltd.
Key market players in the oncology biosimilars market are actively involved in strategic initiatives such as collaborations, partnerships, and product launches to enhance their market presence. Companies like Amgen Inc., Biocon, and Pfizer Inc. are investing significantly in researchThe global oncology biosimilars market is witnessing significant growth, driven by factors such as the increasing prevalence of cancer, rising healthcare costs, and the need for more affordable treatment options. As key market players like Amgen Inc., Biocon, and Pfizer Inc. continue to invest in research and development, the market is expected to expand even further in the coming years. With the potential to reduce the cost burden associated with cancer treatment, biosimilars are becoming increasingly important in the oncology sector.
In terms of product type, monoclonal antibodies, immunomodulators, and supportive care biosimilars are key segments within the oncology biosimilars market. Monoclonal antibodies hold a significant share due to their efficacy in targeting specific cancer cells, while immunomodulators are essential in boosting the immune response against cancer. Supportive care biosimilars play a crucial role in managing side effects of cancer treatment, improving patient quality of life.
The distribution channel segment is also vital in the oncology biosimilars market, with hospitals, retail pharmacies, and online pharmacies playing key roles in the supply chain. Hospitals are major consumers of oncology biosimilars due to the high patient footfall and the need for immediate access to these products. Retail pharmacies provide convenience to patients in accessing biosimilars for home use, while online pharmacies are gaining traction for their easy accessibility and cost-effectiveness.
In terms of applications, oncology biosimilars are utilized in the treatment of various cancers such as breast cancer, lung cancer, colorectal cancer, and others. The growing prevalence of these cancers worldwide is driving the demand for biosimilars as more affordable treatment options. End users of these biosimilars include hospitals, clinics, and ambulatory surgical centers, where the focus is on providing optimal cancer care and improving patient outcomes.
Geographically, North America and Europe are leading markets for oncology biosimilars, driven by well**Global Oncology Biosimilars Market, By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Blood Cancer, Others), Drug Class (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor, Others), Route of Administration (Intravenous, Subcutaneous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029**
The global oncology biosimilars market is witnessing robust growth, driven by the increasing prevalence of cancer and the need for cost-effective treatment options. Biosimilars offer a promising solution to reduce the financial burden associated with cancer care while maintaining similar efficacy and safety profiles as reference biologics. In terms of indication, breast cancer, lung cancer, and colorectal cancer are among the key segments driving demand for oncology biosimilars, reflecting the high incidence of these cancers globally. The drug class segment highlights the importance of monoclonal antibodies and granulocyte colony-stimulating factors in cancer treatment, showcasing the diverse therapeutic options available in the market.
The route of administration is an essential consideration in the oncology biosimilars market, with intravenous and subcutaneous routes being commonly used for drug delivery. This reflects the need for efficient and patient-friendly administration methods in cancer care. End-users such as hospitals,
Oncology Biosimilars Key Benefits over Global Competitors:
- The report provides a qualitative and quantitative analysis of the Oncology Biosimilars Market trends, forecasts, and market size to determine new opportunities.
- Porter’s Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make strategic business decisions and determine the level of competition in the industry.
- Top impacting factors & major investment pockets are highlighted in the research.
- The major countries in each region are analyzed and their revenue contribution is mentioned.
- The market player positioning segment provides an understanding of the current position of the market players active in the Personal Care Ingredients
Table of Contents: Oncology Biosimilars Market
1 Introduction
2 Global Oncology Biosimilars Market Segmentation
3 Executive Summary
4 Premium Insight
5 Market Overview
6 Oncology Biosimilars Market, by Product Type
7 Oncology Biosimilars Market, by Modality
8 Oncology Biosimilars Market, by Type
9 Oncology Biosimilars Market, by Mode
10 Oncology Biosimilars Market, by End User
12 Oncology Biosimilars Market, by Geography
12 Oncology Biosimilars Market, Company Landscape
13 Swot Analysis
14 Company Profiles
Critical Insights Related to the Keyword Included in the Report:
- Exclusive graphics and Illustrative Porter’s Five Forces analysis of some of the leading companies in this market
- Value chain analysis of prominent players in the market
- Current trends influencing the dynamics of this market across various geographies
- Recent mergers, acquisitions, collaborations, and partnerships
- Revenue growth of this industry over the forecast period
- Marketing strategy study and growth trends
- Growth-driven factor analysis
- Emerging recess segments and region-wise market
- An empirical evaluation of the curve of this market
- Ancient, Present, and Probable scope of the market from both prospect value and volume
Browse Trending Reports:
Topical Drug Market
Augmented Reality Market
Building Management System Market
Cnc Controller Market
Gps Tracking Device Market
Energy Harvesting System Market
Industry 4 0 Market
Moisture Analyzer Market
Implantable Drug Delivery Market
Vehicle Analytics Market
Coating Equipment Market
In Vitro Diagnostics Ivd Market
14d Machine Vision Market
Patient Registry Software Market
Composite Bearings Market
Subscriber Data Management Market
Digital Health Technologies Market
Mobile Device Management Market
Oxidative Stress Assay Market
Vaccine Adjuvants Market
Viral Inactivation Market
Sludge Treatment Chemicals Market
Glucose Sensors Market
Gastrointestinal Gi Stent Market
Soy Protein Market
About Data Bridge Market Research:
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Russian
Romaian
Portuguese (Brazil)
Greek